Deucravacitinib
Drug Name(s): Sotyktu
Class: DMARDs
Deucravacitinib is a targeted DMARD used to treat plaque psoriasis and active psoriatic arthritis in adults.
Dosage
Form(s): tablet
6 mg daily
Special Instructions
Your doctor may check you for infection, treat you for tuberculosis (TB) and make sure your vaccines are up to date before you start this drug.
Stop taking and get medical help if you feel faint; have swelling of your face, eyelids, lips, mouth, tongue or throat; have trouble breathing; have tightness in your throat or chest; or develop skin rash or hives.
Before starting this medication, tell your doctor if you are being treated for or have a recurring infection, if you have TB or have been in close contact with someone with TB, or if you have or have had hepatitis B or C.
Call your doctor if you show signs of infection after starting the drug.
Tell your doctor if you are or could become pregnant or breast-feeding.
Do not receive live vaccines before or after starting the medication.
Potential Side Effects
common cold, sore throat, sinus infection, cold sores, acne, mouth sores, inflamed hair follicles
Be Aware
This drug raises the risk of infections, including pneumonia and COVID-19, and malignancies, including lymphomas.
It may also affect certain lab tests, like triglycerides and liver enzymes. Your doctor may order additional lab tests before and during treatment.
It may also raise the risk of potentially serious muscle problems. Tell your doctor if you develop unexplained muscle pain, tenderness, weakness, fatigue, fever or dark-colored urine.
Stay in the Know. Live in the Yes.
Get involved with the arthritis community. Tell us a little about yourself and, based on your interests, you’ll receive emails packed with the latest information and resources to live your best life and connect with others.